Patent
Method for using HIP/PAP polypeptide composition for liver regeneration and prevention of liver failure
| العنوان: | Method for using HIP/PAP polypeptide composition for liver regeneration and prevention of liver failure |
|---|---|
| Patent Number: | 8,329,661 |
| تاريخ النشر: | December 11, 2012 |
| Appl. No: | 13/032521 |
| Application Filed: | February 22, 2011 |
| مستخلص: | This invention is based on the experimental finding that HIP/PAP has mitogenic and antiapoptotic effects in vitro on hepatocytes in primary culture. Moreover, HIP/PAP is a mitogenic and anti-apoptotic molecule for hepatocytcs, in vivo, during liver failure and liver regeneration. The present invention is also based on the experimental finding that HIP/PAP administration has no adverse effects in mammals. This invention concerns a pharmaceutical composition for stimulating liver regeneration in vivo including after chronic/acute liver failure, comprising an effective amount of a polypeptide comprising an amino acid sequence having 90% amino acid identity with the polypeptide consisting of the amino acid sequence starting at the amino acid residue (36) and ending at the amino acid residue (175) of sequence SEQ ID No 1, in combination with at least one physiologically acceptable excipient. |
| Inventors: | Christa, Laurence (Bourg la Reine, FR); Brechot, Christian (Paris, FR); Simon-Gage-Soufflot, Marie-Thérèse (Chaville, FR); Pauloin, Alain (Voisin-le-Bretonneux, FR); Tralhao, J. Guilherme (Coimbra, PT) |
| Assignees: | Instiut National de la Santéet de la Recherche Médicale (INSERM) (Paris, FR), Universite Rene Descartes (Paris, FR) |
| Claim: | 1. A method of stimulating liver regeneration in vivo, protecting against liver failure, or protecting against apoptosis of hepatocytes in a subject comprising: obtaining a pharmaceutical composition comprising a polypeptide comprising an amino acid sequence having at least 90% amino acid identity with an amino acid sequence from amino acid residue 27 to amino acid residue 175 of SEQ ID NO:1; and administering the pharmaceutical composition to a subject, thereby stimulating liver regeneration in vivo, protecting against liver failure, or protecting against apoptosis of hepatocytes, wherein said subject has liver failure, liver necrosis, a liver disease, a partial liver transplant, hepatic cirrhosis, or a hepatic cancer, or wherein said subject has had a liver resection. |
| Claim: | 2. The method of claim 1 , wherein the polypeptide is further defined as comprising an amino acid sequence having at least 90% amino acid identity with the amino acid sequence of SEQ ID NO:1. |
| Claim: | 3. The method of claim 1 , wherein the polypeptide is further defined as comprising an amino acid sequence from amino acid residue 36 to amino acid residue 175 of SEQ ID NO:1. |
| Claim: | 4. The method of claim 3 , wherein the polypeptide is further defined as comprising the amino acid sequence from amino acid residue 27 to amino acid residue 175 of SEQ ID NO:1. |
| Claim: | 5. The method of claim 1 , wherein the polypeptide is further defined as a human hepatocarcinoma-intestine-pancreas/pancreatic-associated protein (HIP/PAP) with the amino acid sequence of SEQ ID NO:1. |
| Claim: | 6. The method of claim 1 , wherein the subject is a human. |
| Claim: | 7. The method of claim 1 , wherein the subject has chronic or acute liver failure. |
| Claim: | 8. The method of claim 1 , wherein the subject has liver necrosis. |
| Claim: | 9. The method of claim 1 , wherein the subject has had a liver resection. |
| Claim: | 10. The method of claim 1 , wherein the subject has a partial liver transplant or hepatic cirrhosis. |
| Claim: | 11. The method of claim 10 , wherein the subject has hepatic cirrhosis of alcoholic, viral, or drug cause. |
| Claim: | 12. The method of claim 1 , wherein the subject has liver failure caused by a disorder selected from the group consisting of Hepatitis B, Hepatitis C, Urea Cycle defects, Familial hypercholesterolemia, Alcohol induced cirrhosis, Glycogen Storage Disease, Autoimmune Hepatitis, Primary Hyperoxaluria type 1, Cryptogenic cirrhosis, Crigler-Najjar syndrome type 1, Congenital Hepatic Fibrosis, Niemann-Pick Disease, Primary Biliary Cirrhosis, Familial Amyloidosis, Biliary Atresia, Hepatocellular Carcinoma, Primary Sclerosing Cholangitis, Hepatoblastoma, Alagille Syndrome, Hemangioendothelioma, Familial Cholestasis, Non-Carcinoid neuroendocrine tumor, Drug induced liver failure, benign liver tumor, liver tumor, Acute liver failure, Budd-Chiari syndrome, Alpha-1-antitrypsin deficiency, Wilson Disease, Hemochromatosis, Tyrosinemia, Protoporphyria, cystic fibrosis, steatosis, non-alcoholic statohepatitis (NASH), and non-alcoholic fatty liver disease (NAFLD). |
| Claim: | 13. The method of claim 1 , wherein the pharmaceutical composition further comprises a therapeutically effective amount of a hepatotoxic compound. |
| Claim: | 14. The method of claim 1 , wherein the subject has a liver disease. |
| Claim: | 15. The method of claim 1 , wherein the subject has liver failure. |
| Claim: | 16. The method of claim 15 , wherein the liver failure is caused by liver disease. |
| Claim: | 17. The method of claim 15 , wherein the liver failure is caused by a liver resection, a liver transplantation, a viral infection, alcohol, or drug poisoning. |
| Claim: | 18. The method of claim 1 , wherein the subject has a hepatic cancer. |
| Claim: | 19. The method of claim 18 , wherein the hepatic cancer is a primary liver tumor or a metastatic liver tumor. |
| Claim: | 20. The method of claim 12 , wherein the subject has Drug induced liver failure. |
| Current U.S. Class: | 514/212 |
| Patent References Cited: | 5834214 November 1998 Iovanna et al. 2011/0144036 June 2011 Christa et al. WO 91/16428 October 1991 |
| Other References: | Moniaux et al, 2011. Hepatology. 53:618-627. cited by examiner Kandil et al, (May 17-22, 2003). Digestive Disease Week Abstracts and Itinerary Planner, Abstract No. 738, 1 page as printed. cited by examiner “Evaluation Report, Research Unit: Physiopathogenesis and treatment of fulminant hepatitis and liver cancer,” French Research and Education Evaluation Agency (AERES), 11 pages, Dec. 2008. cited by other “Guidance for industry—For the submission of chemistry, manufacturing, and controls information for a therapeutic recombinant DNA-derived product or a monoclonal antibody product for in vivo use,” Center for Biologics Evaluation and Research (CBER) and Center for Drug Evaluation and Research (CDER), Aug. 1996. cited by other “Guidance for industry—Q6B specifications: test procedures and acceptance criteria for biotechnological/biological products,” U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), and Center for Biologics Evaluation and Research (CBER), pp. 1-21, Aug. 1999. cited by other “Guideline for industry—Quality of biotechnological products: stability testing of biotechnological/biological products,” Expert Working Group (Quality) of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), pp. 1-10, Jul. 1996. cited by other “Points to consider in the production and testing of new drugs and biologicals produced by recombinant DNA technology,” Office of Biologics Research and Review—Center for Drugs and Biologics, Draft, Apr. 10, 1985. cited by other “Production and quality control of medicinal products derived by recombinant DNA technology,” European Agency for the Evaluation of Medicinal Products (EMEA), pp. 205-216, Dec. 1994. cited by other “Quality of biotechnological products: stability testing of biotechnological/biological products,” European Agency for the Evaluation of Medicinal Products (EMEA), pp. 263-273, Dec. 1995. cited by other “Use of transgenic animals in the manufacture of biological medicinal products for human use,” European Agency for the Evaluation of Medicinal Products (EMEA), pp. 287-294, Dec. 1994. cited by other Bork, “Powers and Pitfalls in Sequence Analysis: The 70% Hurdle,” Genome Research, 10(4):398, 2000. cited by other Brenner, “Errors in genome annotation,” Trends in Genetics, 15(4):132, 1999. cited by other Cervello et al., “Expression of HIP/PAP mRNA in human hepatoma cell lines,” Ann. Ny. Acad. Sci., 963:53-58, 2002. cited by other Christa et al., Hepatocarcinoma-intestine-pancreas/pancreatic associated protein (HIP/PAP) is expressed and secreted by proliferating ducules as well as by hepatocarcinoma and cholangiocarcinoma cells. Am J Pathol, 155:1525-1533, 1999. cited by other Christa et al., “High expression of the human hepatocarcinoma-intestine-pancreas/pancreatic-associated protein (HIP/PAP) gene in the mammary gland of lactating transgenic mice—Secretion into the milk and purification of the HIP/PAP lectin,” Eur. J. Biochem., 267:1665-1671, 2000. cited by other Christa et al., “HIP/PAP is an adhesive protein expressed in hepatocarcinoma, normal Paneth, and pancreatic cells,” Am. J. Physiol., 271:G993-G1002, 1996. cited by other Doerks et al., “Protein annotation: detective work for function prediction ,” Trends in Genetics, 14(6):248, 1998. cited by other Kaufman et al., “Transgenic Analysis of a 100-kb Human beta-Globin Cluster-Containing DNA Fragment Propagated as a Bacterial Artificial Chromosome,” Blood, 94:3178-3184, 1999. cited by other Lasserre et al., “A novel gene (HIP) activated in human primary liver cancer”, Cancer Res., 52:5089-5095, 1992. cited by other Ngo et al., “Computational Complexity Protein Structure Prediction, and the Levinthal Paradox ,“In: The protein folding problem and tertiary structure prediction,” Chapter 14, ,” Eds. Kenneth M. Merz and Scott M. Le Grand, Boston : Birkhäuser , pp. 433-440 and 492-495 only, 1994. cited by other Office Communication, issued in U.S. Appl. No. 10/561,034, dated Sep. 9, 2009. cited by other Office Communication, issued in U.S. Appl. No. 10/561,034, dated Feb. 18, 2010. cited by other Office Communication, issued in U.S. Appl. No. 10/561,034, dated Oct. 26, 2010. cited by other Philipps, “The challenge of gene therapy and DNA delivery,” J. Pharm. Pharmacology, 53:1169-1174, 2001. cited by other Simon Marie-Therese et al., “HIP/PAP stimulates liver regeneration after partial hepatectomy and combines mitogenic and anti-apoptotic functions through the PKA signaling pathway”, Faseb Journal, 17:1441-1450, 2003. cited by other Stolnick et al., “From genes to protein structure and function: novel applications of computational approaches in the genomic era ,” Trends in Biotech., 18(1):34-39, 2000. cited by other Tanaka et al., “Biological effects of human insulin receptor substrate-1 overexpression in hepatocytes,” Hepatology, 26(3):598-604, 1997. cited by other Wang et al., “Rapid analysis of gene expression (RAGE) facilitates universal expression profiling,” Nucl. Acids Res., 27:4609-4618, 1999. cited by other Wells, “Additivity of mutational effects in proteins,” Biochemistry, 29(37):8509-8517, 1990. cited by other Abergel et al., “Crystallization and preliminary crystallographic study of HIP/PAP, a human C-lectin overexpressed in primary liver cancers,” Acta Crystallogr. D. Biol. Crystallogr., 55:1487-1489, 1999. cited by other Hussaini and Farrington, “Idiosyncratic drug-induced liver injury: an overview,” Expert Opin. Drug Saf., 6:673-684, 2007. cited by other Iovanna and Dagorn, “The multifunctional family of secreted proteins containing a C-type lectin-like domain linked to a short N-terminal peptide,” Biochem. Biophys. Acta., 1723:8-18, 2005. cited by other Klaunig et al., “Mouse liver cell culture. I. Hepatocyte isolation,” In Vitro, 17:913-925, 1981. cited by other Manzo et al., “TNF-related apoptosis-inducing ligand: Signaling of a ‘smart’ molecule,” Int. J. Blochem. Cell Biol., 41(3):460-466, 2009. Available online Dec. 28, 2007. cited by other Renton et at., “Effects of polyribonoinosinic acid polyribocytidylic acid and a mouse interferon preparation on cytochrome P-450-dependent monoxygenase systems in cultures of primary mouse hepatocytes,” Mol. Pharmacol., 14(4):672-681, 1978. cited by other Schiesser et al., “Conformational changes of pancreatitis-associated protein (PAP) activated by trypsin lead to insoluble protein aggregates,” Pancreas, 22:186-192, 2001. cited by other |
| Primary Examiner: | Howard, Zachary |
| Attorney, Agent or Firm: | Fulbright & Jaworski L.L.P. |
| رقم الانضمام: | edspgr.08329661 |
| قاعدة البيانات: | USPTO Patent Grants |
| الوصف غير متاح. |